In a recent meta-analysis of eight observational studies involving 161 patients with NF2-associated vestibular schwannomas, the best response to bevacizumab was partial regression in 41%, no change in 47%, and progression in 7% of the patients [86]. The gene discussed is NF2; the disease is Vestibular schwannoma.